Evaluating Consolidative Thoracic Radiotherapy with Atezolizumab Maintenance in Extensive-Stage Small Cell Lung Cancer: Insights from the Phase 2 TREASURE Trial
Posted innews Oncology Respiratory

Evaluating Consolidative Thoracic Radiotherapy with Atezolizumab Maintenance in Extensive-Stage Small Cell Lung Cancer: Insights from the Phase 2 TREASURE Trial

The Phase 2 TREASURE trial investigated the safety and efficacy of adding consolidative thoracic radiotherapy to atezolizumab maintenance in extensive-stage small cell lung cancer, revealing increased toxicity without survival benefit, underscoring the need for cautious patient selection.
Perioperative Nivolumab Combined with Irreversible Electroporation Shows Antitumoral Effect in High-Risk BCLC A Hepatocellular Carcinoma: Results from the NIVOLEP Phase 2 Trial
Posted inGastroenterology news Oncology

Perioperative Nivolumab Combined with Irreversible Electroporation Shows Antitumoral Effect in High-Risk BCLC A Hepatocellular Carcinoma: Results from the NIVOLEP Phase 2 Trial

The NIVOLEP phase 2 trial demonstrates that perioperative nivolumab (neoadjuvant and adjuvant) combined with irreversible electroporation achieves 70.6% one-year local recurrence-free survival in BCLC A HCC patients with high recurrence risk. Pathological response correlated with immune activation pathways, suggesting synergistic effects between immunotherapy and ablation.
Immunotherapy Shows Consistent Efficacy in Recurrent Gynecologic Cancers Regardless of Prior Radiation Field Location
Posted innews OB/GYN & Women's Health Oncology

Immunotherapy Shows Consistent Efficacy in Recurrent Gynecologic Cancers Regardless of Prior Radiation Field Location

This retrospective study challenges the assumption that prior radiation limits immunotherapy effectiveness in recurrent endometrial and cervical cancers, finding no significant difference in response rates or survival outcomes based on recurrence location relative to previous radiotherapy fields.